Oslo

• Extended Criteria Treatment for Liver Metastases With Heavy Tumour Burden Halted
  2024-512397-95-00 4 2026-05-21 Colorectal Liver Metastases
• A Phase 3 Study of NTLA 2001 in participants with amyloidosis with cardiac muscle disease. Halted
  2023-507220-23-00 5 2024-07-26 Transthyretin Amyloidosis with Cardiomyopathy
• A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety … Halted
  2024-516671-33-00 5 2021-05-24 Amyotrophic Lateral Sclerosis
• GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease. Ended
  2025-521107-42-00 4 2025-11-25 Alzheimer's Disease
• Immunosuppressive drug bioequivalence in kidney transplant recipients – Prograf and CellCept Ended
  2025-521800-22-00 6 2025-08-04 Organ transplantation
• A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP Ended
  2024-518364-12-00 4 2025-05-09 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Rebound pain after volar plate surgery in infraclavicular brachial plexus block with ropivacaine 3.75 mg/ml compared with 7.5 mg/ml. A prosp … Ended
  2024-514795-41-00 6 2025-02-14 Radius fracture
• Open-Label Extension of EryDex in A-T (OLE NEAT) Ended
  2024-513618-37-00 5 2024-12-23 Ataxia Telangiectasia (A-T)
• Mangafodipir - an intracellular contrast agent for Magnetic Resonance Imaging (MRI): Measuring manganese uptake rate in heart failure patien … Ended
  2023-508118-40-01 4 2024-11-22 Heart Failure
• Safety Trial, DSC vs. BAT in SR acute GvHD Ended
  2024-511768-97-01 4 2024-11-20 Graft vs Host Disease
• Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization Ended
  2024-512651-20-00 4 2024-11-20 Fetal and Neonatal Alloimmune Thrombocytopenia due to Human Platelet A
• A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended
  2024-511360-87-00 5 2024-10-02 hidradenitis suppurativa (HS)
• CALCIGRAN FORTE AND DOSING OF IMMUNOSUPPRESSIVE DRUGS IN KIDNEY TRANSPLANT RECIPIENTS Ended
  2024-515164-30-00 6 2024-09-25 Kidney transplantation
• A phase 1 study to evaluate the dose, safety and tolerability of a radionuclide therapy (Radspherin®) in patients with platinum sensitive re … Ended
  2024-511851-16-00 1 2024-09-20 Platinum Sensitive Recurrent Epithelial Ovarian, Fallopian Tube or Pri
• A study to test whether BI 1819479 improves lung function in people with idiopathic pulmonary fibrosis (IPF). Ended
  2023-508395-11-00 4 2024-09-10 idiopathic pulmonary fibrosis
• A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis Ended
  2023-510249-79-00 4 2024-09-10 Progressive pulmonary fibrosis (PPF)
• A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy Ended
  2023-508465-32-00 5 2024-09-03 Narcolepsy with Cataplexy (Narcolepsy Type 1)
• A Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Infigratinib in Children with Achondroplasia Ended
  2023-506130-67-00 5 2024-08-20 Achondroplasia
• European randomised clinical trial on mPOX Infection (EPOXI) Ended
  2022-501979-10-00 6 2024-08-08 Monkeypox
• Does human skeletal muscle possess an epigenetic memory of testosterone Ended
  2023-507815-37-00 4 2024-08-01 Healthy aging
• Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia Ended
  2023-508819-23-00 3 2024-07-24 Primary immune thrombocytopenia (ITP)
• Clinical trial of V940 and pembrolizumab in people with resectable locally advanced cutaneous squamous cell carcinoma Ended
  2023-505712-37-00 10 2024-06-06 The participants must have a histologically confirmed diagnosis of res
• A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on subjects with Ataxia-Te … Ended
  2023-509077-23-00 5 2024-06-03 Ataxia Telangiectasia
• EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended
  2023-505083-11-01 4 2024-05-07 Alzheimer's Disease

Showing 409–432 of 508 trials